Imaging Axl expression in pancreatic and prostate cancer xenografts

Biochemical and Biophysical Research Communications

Volumn 443, Issue 2, 2014, Pages 635-640

  Nimmagadda, Sridhar ^a,b   Pullambhatla, Mrudula ^a   Lisok, Ala ^a   Hu, Chaoxin ^c,d   Maitra, Anirban ^b,c,d   Pomper, Martin G ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Axl; Gas6; ImmunoPET; Molecular imaging; Receptor tyrosine kinase

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY I 125; MONOCLONAL ANTIBODY AXL I 125; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE AXL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; MOUSE MODEL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

MUS;

AXL; GAS6; IMMUNOPET; MOLECULAR IMAGING; RECEPTOR TYROSINE KINASE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MICE; MICE, NUDE; MICE, SCID; MOLECULAR IMAGING; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TISSUE DISTRIBUTION;

EID: 84892439508     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.12.014     Document Type: Article

References (31)

1. G. Lemke Biology of the TAM Receptors Cold Spring Harb. Perspect. Biol. 5 11 2013 1 17
2. A. Verma, S.L. Warner, H. Vankayalapati, D.J. Bearss, and S. Sharma Targeting Axl and Mer kinases in cancer Mol. Cancer Ther. 10 10 2011 1763 1773
3. R.M. Linger, A.K. Keating, H.S. Earp, and D.K. Graham TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer Adv. Cancer Res. 100 2008 35 83
4. T.N. Stitt, G. Conn, M. Gore, C. Lai, J. Bruno, C. Radziejewski, K. Mattsson, J. Fisher, D.R. Gies, and P.F. Jones et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases Cell 80 4 1995 661 670
5. G. Berclaz, H.J. Altermatt, V. Rohrbach, I. Kieffer, E. Dreher, and A.C. Andres Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast Ann. Oncol. 12 6 2001 819 824
6. P. Dunne, D.G. McArt, J.K. Blayney, M. Kalimutho, S. Greer, T. Wang, S. Srivastava, C.W. Ong, K.J. Arthur, M. Loughrey, K. Redmond, D.B. Longley, M. Salto-Tellez, P.G. Johnston, and S. Van Schaeybroeck AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early stage colon cancer Clin. Cancer Res. 2013 10.1158/1078-0432.CCR-13-1354
7. A. Hector, E.A. Montgomery, C. Karikari, M. Canto, K.B. Dunbar, J.S. Wang, G. Feldmann, S.M. Hong, M.C. Haffner, A.K. Meeker, S.J. Holland, J. Yu, T.J. Heckrodt, J. Zhang, P. Ding, and D. Goff et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma Cancer Biol. Ther. 10 10 2010 1009 1018
8. M. Hutterer, P. Knyazev, A. Abate, M. Reschke, H. Maier, N. Stefanova, T. Knyazeva, V. Barbieri, M. Reindl, A. Muigg, H. Kostron, G. Stockhammer, and A. Ullrich Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme Clin. Cancer Res. 14 1 2008 130 138
9. L. He, J. Zhang, L. Jiang, C. Jin, Y. Zhao, G. Yang, and L. Jia Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis Mol. Carcinog. 49 10 2010 882 891
10. R.M. Linger, R.A. Cohen, C.T. Cummings, S. Sather, J. Migdall-Wilson, D.H. Middleton, X. Lu, A.E. Baron, W.A. Franklin, D.T. Merrick, P. Jedlicka, D. DeRyckere, L.E. Heasley, and D.K. Graham Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer Oncogene 32 29 2013 3420 3431
11. T. Ito, M. Ito, S. Naito, A. Ohtsuru, Y. Nagayama, T. Kanematsu, S. Yamashita, and I. Sekine Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma Thyroid 9 6 1999 563 567
12. J.B. Koorstra, C.A. Karikari, G. Feldmann, S. Bisht, P.L. Rojas, G.J. Offerhaus, H. Alvarez, and A. Maitra The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target Cancer Biol. Ther. 8 7 2009 618 626
13. Y. Shiozawa, E.A. Pedersen, L.R. Patel, A.M. Ziegler, A.M. Havens, Y. Jung, J. Wang, S. Zalucha, R.D. Loberg, K.J. Pienta, and R.S. Taichman GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche Neoplasia 12 2 2010 116 127
14. J.D. Paccez, G.J. Vasques, R.G. Correa, J.F. Vasconcellos, K. Duncan, X. Gu, M. Bhasin, T.A. Libermann, and L.F. Zerbini The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target Oncogene 32 6 2013 689 698
15. P. Vajkoczy, P. Knyazev, A. Kunkel, H.H. Capelle, S. Behrndt, H. von Tengg-Kobligk, F. Kiessling, U. Eichelsbacher, M. Essig, T.A. Read, R. Erber, and A. Ullrich Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival Proc. Natl. Acad. Sci. USA 103 15 2006 5799 5804
16. S.J. Holland, M.J. Powell, C. Franci, E.W. Chan, A.M. Friera, R.E. Atchison, J. McLaughlin, S.E. Swift, E.S. Pali, G. Yam, S. Wong, J. Lasaga, M.R. Shen, S. Yu, W. Xu, and Y. Hitoshi et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation Cancer Res. 65 20 2005 9294 9303
17. Y.X. Zhang, P.G. Knyazev, Y.V. Cheburkin, K. Sharma, Y.P. Knyazev, L. Orfi, I. Szabadkai, H. Daub, G. Keri, and A. Ullrich AXL is a potential target for therapeutic intervention in breast cancer progression Cancer Res. 68 6 2008 1905 1915
18. Y. Li, X. Ye, C. Tan, J.A. Hongo, J. Zha, J. Liu, D. Kallop, M.J. Ludlam, and L. Pei Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis Oncogene 28 39 2009 3442 3455
19. R.M. Linger, A.K. Keating, H.S. Earp, and D.K. Graham Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors Expert Opin. Ther. Targets 14 10 2010 1073 1090
20. X. Ye, Y. Li, S. Stawicki, S. Couto, J. Eastham-Anderson, D. Kallop, R. Weimer, Y. Wu, and L. Pei An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies Oncogene 29 38 2010 5254 5264
21. L. Cerchia, C.L. Esposito, S. Camorani, A. Rienzo, L. Stasio, L. Insabato, A. Affuso, and V. de Franciscis Targeting Axl with an high-affinity inhibitory aptamer Mol. Ther. 20 12 2012 2291 2303
22. C. Sheridan First Axl inhibitor enters clinical trials Nat. Biotechnol. 31 9 2013 775 776
23. S. Nimmagadda, M. Pullambhatla, and M.G. Pomper Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT J. Nucl. Med. 50 7 2009 1124 1130
24. G. Feldmann, S. Dhara, V. Fendrich, D. Bedja, R. Beaty, M. Mullendore, C. Karikari, H. Alvarez, C. Iacobuzio-Donahue, A. Jimeno, K.L. Gabrielson, W. Matsui, and A. Maitra Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers Cancer Res. 67 5 2007 2187 2196
25. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 1 2013 11 30
26. S.M. Knowles, and A.M. Wu Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology J. Clin. Oncol. 30 31 2012 3884 3892
27. A. Mollard, S.L. Warner, L.T. Call, M.L. Wade, J.J. Bearss, A. Verma, S. Sharma, H. Vankayalapati, and D.J. Bearss Design, synthesis and biological evaluation of a Series of novel Axl kinase inhibitors ACS Med. Chem. Lett. 2 12 2011 907 912
28. M.A. Deri, B.M. Zeglis, L.C. Francesconi, and J.S. Lewis PET imaging with (8)(9)Zr: from radiochemistry to the clinic Nucl. Med. Biol. 40 1 2013 3 14
29. P.P. Sainaghi, L. Castello, L. Bergamasco, M. Galletti, P. Bellosta, and G.C. Avanzi Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor J. Cell Physiol. 204 1 2005 36 44
30. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 65 1-2 2000 271 284
31. J.P. O'Bryan, Y.W. Fridell, R. Koski, B. Varnum, and E.T. Liu The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage J. Biol. Chem. 270 2 1995 551 557